The Path to a Better Tuberculosis Vaccine Runs Through Montana

By Jim Robbins, KFF Health News

April 18, 2024

A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.

The BCG (Bacille Calmette-Guérin) vaccine, created in 1921, remains the sole TB vaccine. While it is 40% to 80% effective in young children, its efficacy is very low in adolescents and adults, leading to a worldwide push to create a more powerful vaccine.

One effort is underway at the University of Montana Center for Translational Medicine. The center specializes in improving and creating vaccines by adding what are called novel adjuvants. An adjuvant is a substance included in the vaccine, such as fat molecules or aluminum salts, that enhances the immune response, and novel adjuvants are those that have not yet been used in humans. Scientists are finding that adjuvants make for stronger, more precise, and more durable immunity than antigens, which create antibodies, would alone.

Click Here to Continue Reading!

Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004

Press Release

May 15, 2024

Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis (NCT06038279). In response to ragweed challenge, participants treated with INI-2004 showed a dose dependent improvement in nasal congestion as measured by acoustic rhinometry compared to placebo participants. Participants treated with INI-2004 exhibited a dose dependent trend towards higher cytokine biomarkers from nasal swab samples compared to placebo. Additionally, all doses of INI-2004 were well tolerated over multiple administrations and no MTD was reached. This follows Inimmune's successful completion of its Phase 1a Single Ascending Dose (SAD) study of INI-2004 in healthy volunteers.

Using a randomized, placebo-controlled, double-blind study design (n=35), INI-2004, a synthetic Toll Like Receptor (TLR) 4 agonist in a mucosal formulation, was delivered intranasally to participants with ragweed allergy. INI-2004 was well tolerated. The adverse events (AEs) were mostly mild in severity, transient, and occurred at a similar rate across INI-2004 and placebo groups. Although this Phase 1b safety study was not powered to measure efficacy, a difference was observed in measured nasal volume between groups. For eligibility, participants were initially dosed with ragweed allergen to produce a 30% decrease in nasal volume, a measure of nasal congestion, as determined by acoustic rhinometry. Eligible participants then received four weekly intranasal administrations of 125, 250, or 500 µg INI-2004 or placebo followed by ragweed challenge after the second and fourth administrations. Acoustic rhinometry was completed multiple times over the course of the study. Participants who received 250 µg and 500 µg doses of INI-2004 had, on average, 34% and 53% improvement, respectively, in nasal volume post ragweed challenge compared to placebo.

Click Here to Continue Reading!

Golden Helix Secures CE Mark for the European Union

By PR Newswire

May 7, 2024

Golden Helix, Inc., a leading provider of clinical bioinformatics solutions, is pleased to announce that it has received CE mark approval for its genetic analysis platform VarSeq Suite. This significant regulatory milestone paves the way for the expansion of Golden Helix's advanced genetic analytics products to the European market, ensuring compliance with the European Union's health, safety, and environmental protection standards.

The CE mark certifies that Golden Helix's genetic analysis platform meets the European In Vitro Diagnostic Regulation (IVDR 2017/746) requirements, which govern the sale of in vitro diagnostic devices within the European Economic Area (EEA). The software must be operated in "Dx Mode" to satisfy the IVDR requirements. Customers will receive specific instructions on how to switch on this compliance mode. With this certification, Golden Helix is poised to assist healthcare providers across Europe in delivering personalized medical diagnostics.

"Obtaining the CE mark is a pivotal step for Golden Helix as we expand internationally," said Dr. Andreas Scherer, President and CEO of Golden Helix. "This approval not only demonstrates our commitment to compliance and quality. It enhances our ability to serve healthcare providers with advanced genetic testing solutions that improve patient outcomes."

Click Here to Continue Reading!

Montana Biotech Companies to Watch 2024

By Melissa Paulsen

May 30, 2024

Since 2017, the Montana High Tech Business Alliance has annually showcased top tech companies in Montana. This year, in partnership with the Montana Bioscience Cluster Initiative, we present the 2024 Montana Biotech Companies to Watch (see the first Biotech 2020 list). These companies are leading the charge in biotech innovation, from improving healthcare for underserved populations to using AI for remote health monitoring and revolutionizing drug discovery with advanced tools.

Key Industry Trends:

1. Female Entrepreneurship: Five of the six firms were founded or led by women, underscoring growing gender diversity in Montana’s entrepreneurial ecosystem.
2. Bozeman - A Biotech Hub: Five of the six companies are based in Bozeman, with two originating as spin-offs from Montana State University, highlighting Bozeman’s growing importance in the biotech sector. 
3. Grant Success: Three firms secured SBIR/STTR grants, showcasing Montana’s high success rate in these competitive federal programs. From 2012 - 2021, Montana's success rate was 18%, surpassing the national average of 16%.
4. Bootstrapping Success: Two companies self-funded their ventures, reflecting Montana’s entrepreneurial history of bootstrapping.

Selection Criteria:

Nominations came from industry partners across Montana, including MonTEC, the Montana Bioscience Alliance, the Missoula Economic Partnership, and others. The six finalists were chosen based on:

• Significant revenue growth or high-growth sector involvement
• Potential to launch impactful products or services
• Valuable intellectual property ownership or development
• Prospects of acquiring major clients or entering new markets
• Expansion plans or significant job creation in the next year
• Management teams led by experienced entrepreneurs or top experts

These innovative businesses are not only advancing the life sciences but also enriching life in Montana.

Here are the 2024 Montana Biotech Companies to Watch:

• IntelligHealth, Bozeman - Advancing remote health monitoring with AI. 
• KLEO, Missoula - Improving healthcare for underserved populations.
• Montana Molecular, Bozeman - Enhancing drug discovery with advanced biosensors.
• NanoMagnetic Solutions, Bozeman - Revolutionizing preclinical drug discovery for brain diseases.
• Titin KM Biomedical, Bozeman - Transforming shoulder injury diagnosis and rehabilitation.
• The Toothpick Company/ KUVU Bio Solutions, Kenya and Bozeman - Innovating biological weed control in agriculture.

Click Here to Continue Reading!

Montana State scientists’ research on RNA editing illuminates possible lifesaving treatments for genetic diseases

By Reagan Cotton, MSU News Service

April 26, 2024

A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases. 

Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in human cells,” was published online Thursday in the journal Science and constitutes the latest advance in the team’s ongoing exploration of CRISPR applications for programmable genetic engineering.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a type of immune system that bacteria use to recognize and fight off viruses. Wiedenheft, one of the nation’s leading CRISPR researchers, said that the system has been used for years to cut and edit DNA, but that applying similar technology to RNA is unprecedented. DNA editing uses a CRISPR-associated protein called Cas9, while editing RNA requires the use of a different CRISPR system, called type-III.

Click Here to Continue Reading!

Anna Nemudraia, left, and Artem Nemudryi are lead authors on a new paper exploring the use of CRISPR technology to edit RNA genetic material. MSU photo by Adrian Sanchez-Gonzalez.

Montana State’s Blake Wiedenheft receives regional award for research excellence

By Reagan Cotton, MSU News Service

July 12, 2024

Montana State University scientist Blake Wiedenheft was recognized last month with a prestigious award from agricultural deans and directors around the Western U.S.

Blake Wiedenheft, a professor in the Department of Microbiology and Cell Biology, was recognized last month for research excellence. MSU photo by Kelly Gorham.

Wiedenheft received the Agricultural Research and Innovation Award from agInnovation West, an organization made up of the experiment station directors and agriculture deans at land-grant universities in the western half of the U.S., plus Hawaii and Alaska. It’s the regional branch of a national group dedicated to innovative research across the land-grant system on topics including food security, nutrition and health, environmental stewardship, and agricultural systems. 

“This award recognizes scientists who strive in their research career to achieve benchmarks reflective of excellence,” said Bret Hess, executive director of agInnovation West, in a letter announcing Wiedenheft’s selection. 



Click Here to Continue Reading!

Montana State receives international recognition for scientific impact

By Reagan Cotton, MSU News Service

JULY 11, 2024

Montana State University has once again been recognized among the top universities in the world for the impact of its scientific discoveries and its collaboration with other researchers.

MSU was featured in the 2024 CWTS Leiden Ranking, which lists more than 1,500 universities worldwide based on their contributions to international scientific journals. The ranking is done by the Centre for Science and Technology Studies, or CWTS, at Leiden University in the Netherlands, and the 2024 edition was based on publication data from 2019-2022. MSU is ranked 168th out of the 206 universities in the U.S. that made the list.



The Leiden ranking is based on articles published in scholarly journals and the impact those publications have on the international community. Impact is measured by the number of times the research is cited in articles by other scientists.

MSU’s world ranking was 1,094th of the 1,506 ranked institutions, with 1,299 published articles during the 2019-2022 period. Nearly a tenth of those articles were among the top 10% of papers in their respective fields, signifying their high impact.

Click Here to Continue Reading!

NIH study shows chronic wasting disease unlikely to move from

animals to people

Study of cerebral organoids reinforces evidence for substantial species barrier

Media Advisory

May 17, 2024

A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people. The findings, from National Institutes of Health scientists and published in Emerging Infectious Diseases, are consistent with decades of similar research in animal models at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Prion diseases are degenerative diseases found in some mammals. These diseases primarily involve deterioration of the brain but also can affect the eyes and other organs. Disease and death occur when abnormal proteins fold, clump together, recruit other prion proteins to do the same, and eventually destroy the central nervous system. Currently, there are no preventive or therapeutic treatments for prion diseases.

CWD is a type of prion disease found in cervids, which are popular game animals. While CWD has never been found in people, a question about its transmission potential has lingered for decades: Can people who eat meat from CWD-infected cervids develop prion disease? The question is important because during the mid-1980s and mid-1990s a different prion disease – bovine spongiform encephalopathy (BSE), or mad cow disease – emerged in cattle in the United Kingdom (U.K.) and cases also were detected in cattle in other countries, including the United States. Over the next decade, 178 people in the U.K. who were thought to have eaten BSE-infected beef developed a new form of a human prion disease, variant Creutzfeldt-Jakob Disease, and died. Researchers later determined that the disease had spread among cattle through feed tainted with infectious prion protein. The disease transmission path from feed to cattle to people terrified U.K. residents and put the world on alert for other prion diseases transmitted from animals to people, including CWD. CWD is the most transmissible of the prion disease family, showing highly efficient transmission between cervids.

Click Here to Continue Reading!

RML Team Targets Transport System as Lyme Disease Treatment

NIAID Now

May 20, 2024

NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria. The study appears in Frontiers in Antibiotics from scientists at NIAID’s Rocky Mountain Laboratories and colleagues at Purdue University.

The strategy involves the oligopeptide (Opp) transport system that most bacteria use as a secondary nutrition route to move small protein-like peptides through the bacteria. But B. burgdorferi, the researchers learned in a 2017 study, depends on the Opp system for survival, growth, and replication. They subsequently hypothesized that if they could impede the Opp system, maybe the bacterium would stop growing and die.

To test their theory they developed a method to screen 2,240 chemical compounds from a commercial library used for small-molecule drug discovery. They wanted to know if any compounds would bind to a prominent transport system protein known as OppA2. The research team identified eight compounds that did so, and of those, two compounds – C2 and C7 – significantly slowed B. burgdorferi growth, making the Opp system a viable, previously unexplored treatment target.

Click Here to Continue Reading!

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems 

News Provided by SPI Pharma, Inc. 

July 16, 2024

SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune's world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma's extensive manufacturing and global commercial capabilities.

Adjuvant systems are critical components of vaccines that enhance immune response and efficacy. The partnership will aim to provide reliable supply and open access to advanced adjuvant systems, addressing significant unmet needs in vaccine development and accelerating the availability of these technologies to healthcare providers and patients globally.

Click Here to Continue Reading!

The Montana Bioscience Alliance is excited to announce its participation in the 2024 BIO International Convention. The alliance, accompanied by the Montana Department of Commerce and Montana Technology Innovation Partnership, hosted several Montana bioscience companies at the exhibitor booth, showcasing the state’s diverse and innovative bioscience landscape. This platform provides a unique opportunity for Montana companies to connect with global industry leaders, investors, and potential partners.

In addition to the exhibitor booth this year, MTBSA co-hosted the Peaks & Piers: A Montana-San Diego Innovation Summit, with Two Bear Capital and MTBSA board chair, Cynthia Tsai. This was an unforgettable evening of connection and inspiration. The event brought together a dynamic group of bioscience and technology leaders from both states, fostering new partnerships and collaborations. Attendees enjoyed breathtaking ocean views while networking and exploring opportunities to bridge the gap between Montana’s natural resources and San Diego’s innovation ecosystem.



A highlight of the evening was the insightful discussion by Cynthia Tsai, Montana Bioscience Board Chair, and Michael Goguen, Founder and Managing Partner of Two Bear Capital. Their expertise and passion ignited conversations about the future of the bioscience industry and the potential for groundbreaking discoveries. The enthusiasm generated at Peaks & Piers is a testament to the thriving innovation ecosystem in Montana.

Early Bird Entry: June 25–September 8, 2024 (Fee $100)

2025 SXSW Pitch Categories

• AgTech & Food (new for 2025)
• Enterprise, Smart Data, FinTech & Future of Work
• Entertainment, Media, Sports & Content
• Extended Reality, Web3, Voice & Robotics
• HealthTech, MedTech, BioTech & Accessibility (new for 2025)
• Innovative World Tech
• Security, GovTech & Space (new for 2025)
• Smart Cities, Transportation & Sustainability
• Student Startups

SXSW Pitch Eligibility Criteria

• The company’s product and/or service must have been conceived no earlier than January 1, 2022.

• Each company may only enter one product or service into SXSW Pitch. A company that enters multiple products or services is not eligible to participate in SXSW Pitch.

• Startups are encouraged to apply to multiple SXSW competitions — SXSW Pitch, SXSW Innovative Awards, and SXSW EDU Launch (if you are an education-related startup). But because we want to showcase as many different compelling startups as possible at SXSW, know that your startup will only be selected as a finalist in one of these three competitions.

• Founders of the company applying must retain some portion of ownership.

• The Company must not have raised over ten (10) Million Dollars in funding from combined funding sources. 

• Startups should be legally registered and compliant with all relevant regulations and laws in their respective jurisdictions.

• The product or service must fall into one of the SXSW Pitch categories.

Learn more here.

Evergreen Bioscience Events: Executive Collaboration &

Solutions Summit

We are delighted to invite you to two pivotal events co-hosted by the Montana Bioscience Alliance and Evergreen Bioscience Innovation Cluster. These events are designed to foster collaboration and drive innovation across the bioscience industry.

Evergreen Executive Collaboration

Date: August 6, 2024

Time: 5:30 PM - 8:00 PM

Location: Gallatin River Lodge, 9105 Thorpe Rd, Bozeman, MT

Highlights:

• Networking with top bioscience executives
• Identification and voting on critical industry challenges
• Paving the way for actionable solutions

RSVP: Executive Collaboration RSVP

Evergreen Solutions Summit

Date: August 7, 2024

Time: 8:30 AM - 11:00 AM

Location: Montana State University, Inspiration Room, Norm Asbjornson Hall Bldg, W Grant St, Bozeman, MT

Highlights:

• Executive-proposed problem statements
• Collaborative solution development
• Voting on the most implementable and effective solutions

RSVP: Solutions Summit RSVP

These events are part of a three-step process aimed at eliminating barriers to bioscience industry growth. By participating, you will be contributing to shaping the future of bioscience innovation.

Attention Small Businesses in Montana, New Mexico, and Wyoming!

Are you planning a near-term NSF SBIR/STTR Phase I proposal?

Join us on August 8th over Zoom for our FAST collaborative NSF Proposal Lab. This one-day intensive event, hosted by Montana Innovation Partnership powered by MSU TechLink Center, the Wyoming Small Business Development Center Network, and NM FAST, will provide you with successful proposal development strategies and specific guidance on National Science Foundation (NSF) SBIR/STTR Phase I applications.

Don't miss this valuable opportunity to enhance your proposal!

BioJapan, Regenerative Medicine, Healthtech Trade Show Opportunity in October

Sign up now: Montana Pavilion at BioJapan

Are you interested in selling your bio-related products into Japan? Participate in our Montana Pavilion at the BioJapan Trade Show this October; this event will be focused on the biotechnology, regenerative medicine and healthtech sectors.

There is little to no cost for you to participate. In collaboration with the Montana World Trade Center, the Montana Bioscience Cluster Initiative and Montana’s Trade Office in Japan, ExportMontana will pay for a booth and furniture via our Montana State Trade Expansion Program (STEP) grant, funded by a U.S. Small Business Administration grant. Additionally, up to $2,000 in travel costs for one of your staff can be reimbursed from our grant program.

Interested? Complete the online grant application.

Why BioJapan?

BioJapan is the largest show in Japan focused on the bio industry. This show will bring together three components to be one of the best partnering opportunities for the industry: Biotechnology, regenerative medicine and healthtech (learn more about the show and attendees here).

For More Information, Click Here!

2024 Stibitz-Wilson Awards

Code to Cure: Celebrating Visionaries at the Nexus of Medicine and Technology

Date: September 20, 2024 

Time: 5:00 PM 

Location: The ELM Theater, North 7th Street, Bozeman, MT

The Montana Bioscience Alliance is proud to sponsor the 2024 Stibitz-Wilson Awards, hosted by the American Computer & Robotics Museum. Join us for an inspiring evening honoring visionaries in medicine and technology. This year’s theme, "Code to Cure: Visionaries at the Nexus of Medicine and Technology," celebrates pioneers like Maya Ajmera, Dr. Charles Limb, Dr. Russell Taylor, and Dr. Irving Weissman. The event is free and open to the public. Don’t miss this opportunity to connect with leaders shaping the future of healthcare and innovation.

For more information, visit acrmuseum.org/awards.

Rocky Mountain Life Sciences Investor and Partnering Conference

Thursday, September 12 — Friday, September 13

Beaver Run Resort & Conference Center | 620 Village Road | Breckenridge, CO

Registration is open for CBSA’s 2024 Rocky Mountain Life Sciences Investor and Partnering Conference!

With so much interest in this event, we have outgrown the venue in Vail and are moving the conference to a newly renovated, spacious venue in Breckenridge, Colorado with a fresh conference format. 

The event will kick-off with a keynote lunch on September 12, and end by noon on September 13.

For more information, or if you have interest in sponsoring, contact Emily Martini, Vice President of Partnerships.

Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR

Are you interested in supporting more diversity and inclusion in your biotechnology? The National Institute on Aging (NIA) Small Business Program is accepting applications for Diversity Supplements, which are administrative funds (up to $250,000 in direct costs) to enhance the research and entrepreneurial workforce's diversity by recruiting and supporting students, post-docs, and eligible investigators from underrepresented groups in health-related research into the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. 

Scientists, entrepreneurs, and trainees from diverse backgrounds and life experiences bring unique perspectives, creativity, and individual enterprise to address complex scientific problems. Participation by minority, socially and economically disadvantaged, and women-owned small businesses is critical to the success of the SBIR and STTR programs as well as to the development of new treatments, technologies, and products that address healthy aging. NIA strives to identify, develop, and support researchers by fostering diversity in the workforce through the SBIR and STTR programs and encourages you to consider applying for the Administrative Supplements to Promote Diversity in Research and Development Small Businesses - SBIR/STTR.

• Deadline: NIA accepts applications on a rolling basis. Applications received by the second Thursday of the month will be reviewed the following month. Applications received after the second Thursday of the month will be reviewed within two months.

• Eligibility: Phase I and Phase II SBIR and STTR applicants are encouraged to apply for diversity supplements. At the time of supplement application, parent SBIR and STTR grants must have a minimum of 8 months remaining to ensure sufficient time and opportunity for diversity-based candidates to gain experience. 

• Candidates: High school, undergraduate, post-baccalaureate, master’s, Ph.D., postdoctoral, and eligible new investigator candidates from groups that are underrepresented in biomedical research, such as individuals from underrepresented racial/ethnic groups, with a disability, or from disadvantaged backgrounds. 

Thank you again for your interest in the NIA SBIR and STTR programs. Please follow us on LinkedIn and Twitter to join the conversation and our NIA Small Business community. For more information, please contact Armineh Ghazarian.

The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The application due dates are January 5th, April 5th and September 5th, so start preparing your application today. As usual, there are four Omnibus Solicitations:

• PA-23-230: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

• PA-23-231: PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

• PA-23-232: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

• PA-23-233: PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Please note: The SBIR and STTR Extension Act of 2022 (the Act), signed into law by President Biden on September 30, 2022, reauthorized the SBIR program, the STTR program, and related pilot programs through September 30, 2025.

The Act includes major changes to the SBIR and STTR programs, including:

• increased minimum performance standards (refer to NOT-OD-23-092),
• Pre- and Post- award foreign disclosure requirements (refer to NOT-OD-23-139, view the required form)

Additionally, peer review criteria have changed. As these are significant changes, applicants are urged to read the solicitations in full.

Questions? Contact SEEDinfo@nih.gov.

Open Positions:



-Laboratory Services Manager

-Technician - APEX

-Apex Lab Analyst

To find out more about the current open positions and about Mesa Labs, Click Here!

Careers at Inimmune

Join the Inimmune team in beautiful Missoula, Montana. Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology.We are always looking for talented people. If we do not have any available positions posted, contact us directly to inquire.

Send your Resume

Inimmune is always interested in creative, enthusiastic scientists with experience in synthetic chemistry, formulation and analytical development, or immunology. If you would like to be part of our team, please email your resume to HR@Inimmune.com



To find out more about the current open positions and about Inimmune, Click Here!

Careers at FYR Diagnostics

FYR Diagnostics is a fast growing Missoula, MT-based biotechnology company developing a powerful portfolio of PCR-focused solutions. FYR Diagnostics’ mission is to commercialize novel detection technologies to help eliminate human suffering by better diagnosing human disease states and to eliminate vast inefficiencies in the agricultural industry.

Those who work with FYR Diagnostics are members of a community that seeks to respect and celebrate all the qualities that make each of us unique. Each of us is empowered to be ourselves within this community, which cultivates and promotes equity, diversity, and inclusion at all levels. FYR Diagnostics is proud to be an Equal Opportunity Workplace and Affirmative Action Employer.

Ready to FYR up your career? We are hiring across our organization. Please contact us if you don’t see an open position that is a fit and think we may be the right place for you.

To find out more about the current open positions, Click Here!

Two Bear Capital provides a job board with the different job openings from

the following companies:

-Abilita Bio

-CIQ

-Elisity

-FYR Diagnostics

-Graphiant

-Inimmune

-Novoron Bioscience

-pulseData

-Selector AI

-TileDB

For Open positions with Companies you'll love to work for, Click Here!

Work for a great company in beautiful Bozeman, MT

At Golden Helix, we are committed to accelerating ground-breaking research in genetics, drug discovery and predictive analytics, to our purpose of dramatically improving human health, our great culture, personal development, and strong values.

We are always seeking self-motivated individuals who strive for excellence and have the drive to help us on our journey. We offer competitive wages, benefits and the opportunity to live in one of the most beautiful areas in the world.

Open Positions:

-Area Sales Director

-Director of Renewal Sales

-Finance Manager

-Operations Coordinator

General Employment Inquiries

Interested in a position that we're not actively hiring? Submit your resume for our files! We will archive your information and if a position becomes available that matches your qualifications, we'll contact you.

Click here to apply!

Open Solicitations From Techlink and MTIP

Dates are subject to change. Please refer to each agency site for up-to-date information.

• NIH Targeted funding announcements have varying release and due dates. Find a list of currently open program announcements and requests for applications here.

Identify a participating agency or agencies interested in your topic area, Click Here.

Different participating agencies fund different sectors and technology areas, so a first step is to see which agency or agencies fund projects relevant to you. Agencies also differ in how narrow or broadly they define their topic areas. Current Topics - Search technology topic areas that agencies are interested in funding right now.

Reach out today for no-cost consulting and proposal reviews from one of MTIP's SBIR

experts.

Montana SBIR/STTR Matching Funds Program

What do you do after you have received Stage 1 SBIR/STTR matching funds from the Montana Department of Commerce, have satisfactorily completed your Phase I work, the Phase I final report has been accepted by the Federal SBIR/STTR agency, and you have submitted your SBIR or STTR Phase II proposal?

You submit your Stage 2 application to the Montana SBIR/STTR Matching Funds Program. You do not have to receive notification of a Phase II award before submitting this application. For more information, Click Here!

Questions? Feel free to contact Ann at ann.peterson@montana.edu or

Annmarie Robinson with the Department of Commerce at arobinson3@mt.gov.

How would you like to have more free time to focus on innovating and growing your business?

Are you ready to clear your plate of time-consuming daily HR tasks — such as payroll, benefits, talent, and compliance? Right now's the perfect time to see if ADP’s PEO is the right move for you, too.

What is ADP TotalSource?

• Endorsed by BIO for life science companies of any size.
• Full-service PEO (professional employer organization) partner with coverage in all 50 states
• Partner to help you attract and retain top talent more easily with access to ADP Recruiters, HR advisors and best-in-class benefits.
• Industry-leading PEO, giving you confidence that ADP does it the right way.

As an IRS certified and ESAC accredited PEO, ADP meets the highest standards for financial responsibility, ethical business conduct, and regulatory compliance.

Now is the time to start the process if you want to make a change for 2024.

UPS Healthcare brings reliability, scalability and security to life science companies every day. Its portfolio of end-to-end services is well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Learn exactly how from UPS Healthcare.

Through Montana BioScience Alliance’s partnership with UPS Healthcare, you get access to exclusive rates on a full suite of UPS® services. And, after recent renegotiations, the savings have gotten even better. While the same popular shipping services, like UPS Next Day Air®, and UPS Worldwide Express SM, remain at reduced rates, the price band range to qualify for discounts is narrower. For example, a company that spends $1,500 to $4,999.99 weekly for UPS Next Day Air® shipping now receives a 60% discount rather than a 50-55% discount under the previous arrangement.

As a Montana BioScience Alliance member, be confident that your critical healthcare shipments will be delivered timely and with care by a quality-focused and patient-driven organization.

Montana BioScience Alliance Members Save Up To:

· 74% on UPS Next Day Air®

· 59% on UPS 2nd Day Air® & UPS 3 Day Select Services®

· 51% on UPS Ground® Commercial Services

· 68% on UPS Worldwide International Services